Borealis Biosciences, Inc.

Based in Vancouver, Canada, Borealis Biosciences, Inc. is a biotechnology company focused on developing RNA medicines for treating chronic kidney diseases through innovative therapeutic approaches. Founded in 2024, Borealis Biosciences, Inc. specializes in RNA medicines targeting kidney diseases.

The company is headquartered in Vancouver, Canada. CEO Christian Hordo leads the company, which has raised a total of USD 30 mn through its Series A funding round on December 19, 2024, with Westlake Village BioPartners as the lead investor. Borealis has completed 2 deals to date. Borealis Biosciences specializes in developing RNA medicines aimed at treating kidney diseases, capitalizing on a convergence of scientific and translational breakthroughs.

The company’s primary focus is on addressing chronic kidney diseases, which affect approximately 1 in 7 individuals globally. Their innovative RNA therapeutic approaches target specific kidney cell subpopulations that traditional small molecule and biologic modalities have not effectively addressed. Borealis’s efforts are concentrated on regions with significant unmet medical needs in kidney disease treatment, potentially including North America, Europe, and Asia. Borealis Biosciences has secured USD 150 mn in funding from Versant Ventures and Novartis, indicating strong investor confidence.

The company anticipates generating revenue through partnerships and collaborations with pharmaceutical and biotech firms, as well as potential licensing agreements for its RNA therapeutics. The revenue model may involve collaborative research agreements and milestone payments linked to the development and commercialization of its products, alongside potential income from royalties on successful launches or treatments. In December 2024, Borealis Biosciences raised USD 30 mn in Series A funding led by Westlake Village BioPartners. This funding will be utilized to advance the company’s RNA-based therapeutic programs targeting kidney diseases.

Borealis is focused on expanding its product development initiatives and exploring new geographic markets to address unmet medical needs by leveraging the recent funding.